ACAD ACADIA Pharmaceuticals Inc.

+0  (1%)
Previous Close 32.35
Open 32.45
Price To book 7.57
Market Cap 3.96B
Shares 121,407,000
Volume 787,572
Short Ratio 10.10
Av. Daily Volume 1,833,640

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated November 2016.
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016.
Adjunctive treatment of schizophrenia
Phase 2 trial initiated October 2016.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016
Parkinson’s disease psychosis (PDP)
Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed.
Alzheimer’s disease psychosis

Latest News

  1. ETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 19, 2017
  2. What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
  3. ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
  4. ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
  5. 3 Top Biotech Stocks to Buy in 2017
  6. Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology
  7. ETFs with exposure to ACADIA Pharmaceuticals, Inc. : March 6, 2017
  8. ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
  9. Edited Transcript of ACAD earnings conference call or presentation 28-Feb-17 10:00pm GMT
  10. Acadia Beats Analysts Estimates
  11. ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
  12. ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
  13. Will Acadia Beat Estimates Again? Maybe.
  14. ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
  15. JANA Partners Made Massive New Pharma Investments in Q4
  16. ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
  17. Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
  18. Acadia Pharmaceuticals Surge Higher Is More Than M&A Rumors
  19. Price Bump From M&A Rumors Earns Acadia A Vetr Downgrade